---
document_datetime: 2025-01-07 11:14:33
document_pages: 13
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/simbrinza-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: simbrinza-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 6.6279764
conversion_datetime: 2025-12-20 19:00:44.548928
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## SIMBRINZA

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0028/G          | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - | 19/12/2024                          |                                             | Annex II and PL                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | responsible for importation and/or batch release - Not including batch control/testing A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient   |            |            |              |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------|-----------------------------------|
| PSUSA/10273 /202206 | Periodic Safety Update EU Single assessment - brinzolamide / brimonidine tartrate                                                                                                                                                                                                                                                                                                                                                                                | 09/02/2023 | n/a        |              | PRAC Recommendation - maintenance |
| IA/0026             | B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                                                                                                                                                                                                                                                                                      | 14/12/2022 | n/a        |              |                                   |
| IB/0024/G           | This was an application for a group of variations. C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                  | 10/12/2022 | 11/01/2024 | SmPC and PL  |                                   |
| IAIN/0023/G         | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                               | 30/09/2021 | 29/09/2022 | Annex II and |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer   |            |     | PL   |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|-----------------------------------|
| PSUSA/10273 /202006 | Periodic Safety Update EU Single assessment - brinzolamide / brimonidine tartrate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 11/02/2021 | n/a |      | PRAC Recommendation - maintenance |
| IB/0021/G           | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 05/10/2020 | n/a |      |                                   |

<div style=\"page-break-after: always\"></div>

|             | batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time   |            |     |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IAIN/0020/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 18/03/2020 | n/a |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |      |                                                                                                                                                                 |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0018/G | This was an application for a group of variations. Update of section 5.1 of the SmPC in order to update the safety information with adjunctive use of BID Simbrinza with a PGA therapy based on final results from study CQVJ499A2401; this is a phase 4, multicenter, randomized, double-masked, parallel- group study. Update of section 5.1 of the SmPC in order to update the safety information with adjunctive use of BID Simbrinza with a PGA/beta-blocker combination therapy based on final results from study CQVJ499A2402; this is a phase 4, multicenter, randomized, double-masked, parallel-group study. The requested group of variations proposed amendments to the Summary of Product Characteristics. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 07/11/2019 | 15/09/2020 | SmPC | The SmPC section 5.1 has been updated with safety information with adjunctive use of BID Simbrinza with a PGA therapy and PGA/beta-blocker combination therapy. |

<div style=\"page-break-after: always\"></div>

| II/0019             | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   | 31/10/2019   | n/a        |                                  |                                                                                                                                                                                                                                                                         |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0017             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                   | 15/07/2019   | 15/09/2020 | SmPC                             |                                                                                                                                                                                                                                                                         |
| IA/0016             | B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                                                                                                                      | 30/04/2019   | n/a        |                                  |                                                                                                                                                                                                                                                                         |
| R/0014              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                          | 13/12/2018   | 20/02/2019 | SmPC, Labelling and PL           | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of SIMBRINZA in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| PSUSA/10273 /201806 | Periodic Safety Update EU Single assessment - brinzolamide / brimonidine tartrate                                                                                                                                                                                                                | 17/01/2019   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                       |
| IA/0013             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                   | 23/08/2018   | 20/02/2019 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                         |
| T/0012              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                              | 20/03/2018   | 19/04/2018 | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                         |
| IB/0011/G           | This was an application for a group of variations.                                                                                                                                                                                                                                               | 20/02/2018   | n/a        |                                  |                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.d.1.a.1 - Stability of AS - Change in the re-test period/storage period - Reduction B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation - Change in the specification parameters   | B.I.c.2.z   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|

<div style=\"page-break-after: always\"></div>

|                     | Other variation B.I.z - Quality change - Active substance - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                        |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/10273 /201706 | Periodic Safety Update EU Single assessment - brinzolamide / brimonidine tartrate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 11/01/2018 | n/a        |                        | PRAC Recommendation - maintenance |
| T/0009              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 06/04/2017 | 08/05/2017 | SmPC, Labelling and PL |                                   |
| IB/0008/G           | This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation | 14/02/2017 | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10273 /201606 | Periodic Safety Update EU Single assessment - brinzolamide / brimonidine tartrate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 12/01/2017 | n/a | PRAC Recommendation - maintenance |
| IB/0007/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new | 06/12/2016 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | corresponding test method B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition   |            |     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0005/G | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new                                                                                                                              | 26/07/2016 | n/a |

<div style=\"page-break-after: always\"></div>

| corresponding test B.I.b.2.a - Change starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change starting material/reagent/intermediate changes to an approved   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)   |            |            |                 |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| PSUSA/10273 /201506 | Periodic Safety Update EU Single assessment - brinzolamide / brimonidine tartrate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 14/01/2016 | n/a        |                 | PRAC Recommendation - maintenance |
| PSUSA/10273 /201412 | Periodic Safety Update EU Single assessment - brinzolamide / brimonidine tartrate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 09/07/2015 | n/a        |                 | PRAC Recommendation - maintenance |
| IA/0003             | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 29/05/2015 | 11/02/2016 | SmPC and PL     |                                   |
| IB/0001/G           | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any                                                                                                                                                                                                                                                                                                       | 16/02/2015 | 11/02/2016 | Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

| manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|